Skip to main content

Table 2 Demographic and clinical characteristics of patients in the study (n = 38,842) and matched (n = 9864) cohorts

From: The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study

Characteristic Study Cohort   Matched Cohort  
Aspirin
(n = 4979)
No Aspirin
(n = 33,863)
P-value Standardized difference Aspirin
(n = 4932)
No Aspirin
(n = 4932)
P-value Standardized difference
Age, years (mean ± SD) 71.48 ± 9.51 64.93 ± 12.21 < 0.0001* 0.599 71.41 ± 9.50 71.93 ± 9.55 0.065 0.055
Age    < 0.0001*     0.0913  
 < 65, n (%) 1060 (21.29) 15,191 (44.86)   0.517 1057 (21.43) 989 (20.05)   0.034
 ≥65, n (%) 3919 (78.71) 18,672 (55.14)   0.517 3875 (78.57) 3943 (79.95)   0.034
Sex, n (%)    < 0.0001*     0.28  
 Male 3245 (65.17) 20,536 (60.64)   0.094 3205 (64.98) 3256 (66.02)   0.022
 Female 1734 (34.83) 13,327 (39.36)   0.094 1727 (35.02) 1676 (33.98)   0.022
Income (NTD), n (%)    < 0.0001*     0.2085  
 0 (Dependent) 1036 (20.81) 5841 (17.25)   0.091 1024 (20.76) 1074 (21.78)   0.025
 1–15,840 991 (19.90) 5476 (16.17)   0.097 978 (19.83) 1009 (20.46)   0.016
 15,841–25,000 2226 (44.71) 16,673 (49.24)   0.091 2209 (44.79) 2190 (44.40)   0.008
 ≥25,000 726 (14.58) 5873 (17.34)   0.075 721 (14.62) 659 (13.36)   0.036
Urbanization, n (%)    0.5737     0.5648  
 1 (City) 1380 (27.72) 9088 (26.84)   0.020 1367 (27.72) 1354 (27.45)   0.006
 2 2141 (43.00) 14,758 (43.58)   0.012 2120 (42.98) 2124 (43.07)   0.002
 3 912 (18.32) 6193 (18.29)   0.001 906 (18.37) 875 (17.74)   0.016
 4 (Village) 546 (10.97) 3824 (11.29)   0.010 539 (10.93) 579 (11.74)   0..026
CCI, n (%)    < 0.0001*     0.3988  
 ≤6 2994 (60.13) 17,441 (51.50)   0.174 2955 (59.91) 2996 (60.75)   0.017
 > 6 1985 (39.87) 16,422 (48.50)   0.174 1977 (40.09) 1936 (39.25)   0.017
Comorbidities, n (%)
 Acute myocardial infarction 339 (6.81) 314 (0.93) < 0.0001* 0.309 295 (5.98) 249 (5.05) 0.0425 0.041
 Ischemic cerebrovascular accident 138 (2.77) 488 (1.44) < 0.0001* 0.903 134 (2.72) 127 (2.58) 0.6606 0.009
 Chronic kidney disease 293 (5.88) 932 (2.75) < 0.0001* 0.155 285 (5.78) 274 (5.56) 0.6319 0.010
 Diabetes mellitus 1851 (37.18) 6507 (19.22) < 0.0001* 0.407 1825 (37.00) 1802 (36.54) 0.6310 0.010
 Hypertension 3954 (79.41) 15,041 (44.42) < 0.0001* 0.773 3907 (79.22) 3979 (80.68) 0.0702 0.036
 Dyslipidemia 2289 (45.97) 7666 (22.64) < 0.0001* 0.507 2248 (45.58) 2170 (44.00) 0.1143 0.032
 Atrial fibrillation 380 (7.63) 696 (2.06) < 0.0001* 0.262 372 (7.54) 335 (6.79) 0.1487 0.029
 GI bleeding 228 (4.58) 1067 (3.15) < 0.0001* 0.074 225 (4.56) 211 (4.28) 0.4928 0.014
Lung cancer treatment, n (%)
 Chemotherapy 4057 (81.48) 28,723 (84.82) < 0.0001* 0.089 4027 (81.65) 4033 (81.77) 0.8758  
 Erlotinib 720 (14.46) 4637 (13.69) 0.1426 0.022 713 (14.46) 646 (13.10) 0.0503 0.039
 Gefitinib 1034 (20.77) 6351 (18.75) 0.0007* 0.051 1018 (20.64) 943 (19.12) 0.0585 0.038
 Radiotherapy 2575 (51.72) 18,446 (54.47) 0.0003* 0.055 2554 (51.78) 2539 (51.48) 0.7625 0.006
  1. Statistical significance is define by P<0.05. P values were marked "*" if they were below this threshold